176 related articles for article (PubMed ID: 33469357)
1. Triple-Negative Breast Cancer: Assessing the Role of Immunohistochemical Biomarkers on Neoadjuvant Treatment.
da Silva JL; Rodrigues FR; de Mesquita GG; Fernandes PV; Thuler LCS; de Melo AC
Breast Cancer (Dove Med Press); 2021; 13():31-44. PubMed ID: 33469357
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of EGFR and cytokeratin 5/6 immunohistochemical expression in triple-negative breast cancer.
Abdelrahman AE; Rashed HE; Abdelgawad M; Abdelhamid MI
Ann Diagn Pathol; 2017 Jun; 28():43-53. PubMed ID: 28648939
[TBL] [Abstract][Full Text] [Related]
4. Pathologic and immunohistochemical prognostic markers in residual triple-negative breast cancer after neoadjuvant chemotherapy.
Ilie SM; Briot N; Constatin G; Ilie A; Beltjens F; Ladoire S; Desmoulins I; Hennequin A; Bertaut A; Coutant C; Causeret S; Ghozali N; Coudert B; Arnould L
Front Oncol; 2023; 13():1309890. PubMed ID: 38273853
[TBL] [Abstract][Full Text] [Related]
5. Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer.
Miglietta F; Dieci MV; Tsvetkova V; Griguolo G; Vernaci G; Menichetti A; Faggioni G; Giarratano T; Mioranza E; Genovesi E; Cumerlato E; Bottosso M; Saibene T; Michieletto S; Lo Mele M; Conte P; Guarneri V
Oncologist; 2020 Sep; 25(9):e1355-e1362. PubMed ID: 32618068
[TBL] [Abstract][Full Text] [Related]
6. [Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].
Ma WY; Zhang P; Zhang BL; Wang X; Xu XZ; Zheng S; Wang JY; Cai RG; Yuan P; Ma F; Fan Y; Xu BH
Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):770-4. PubMed ID: 23291072
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Influence of Residual Tumor-Infiltrating Lymphocyte Subtype After Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
da Silva JL; de Albuquerque LZ; Rodrigues FR; de Mesquita GG; Fernandes PV; Thuler LCS; de Melo AC
Front Oncol; 2021; 11():636716. PubMed ID: 34858800
[TBL] [Abstract][Full Text] [Related]
8. Lack of Androgen Receptor Expression Selects for Basal-Like Phenotype and Is a Predictor of Poor Clinical Outcome in Non-Metastatic Triple Negative Breast Cancer.
Riaz N; Idress R; Habib S; Lalani EN
Front Oncol; 2020; 10():1083. PubMed ID: 32850312
[No Abstract] [Full Text] [Related]
9. Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer.
Yuan Y; Lee JS; Yost SE; Li SM; Frankel PH; Ruel C; Schmolze D; Robinson K; Tang A; Martinez N; Stewart D; Waisman J; Kruper L; Jones V; Menicucci A; Uygun S; Yoder E; van der Baan B; Yim JH; Yeon C; Somlo G; Mortimer J
Oncologist; 2021 Mar; 26(3):e382-e393. PubMed ID: 33098195
[TBL] [Abstract][Full Text] [Related]
10. The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer.
Adamo B; Ricciardi GRR; Ieni A; Franchina T; Fazzari C; Sanò MV; Angelico G; Michele C; Tuccari G; Adamo V
Oncotarget; 2017 Sep; 8(44):76974-76986. PubMed ID: 29100362
[TBL] [Abstract][Full Text] [Related]
11. Sociodemographic, Clinical, and Pathological Factors Influencing Outcomes in Locally Advanced Triple Negative Breast Cancer: A Brazilian Cohort.
da Silva JL; de Paula BHR; Small IA; Thuler LCS; de Melo AC
Breast Cancer (Auckl); 2020; 14():1178223420962488. PubMed ID: 33029072
[TBL] [Abstract][Full Text] [Related]
12. Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer.
Agostinetto E; Losurdo A; Nader-Marta G; Santoro A; Punie K; Barroso R; Popovic L; Solinas C; Kok M; de Azambuja E; Lambertini M
Expert Opin Investig Drugs; 2022 Jun; 31(6):567-591. PubMed ID: 35240902
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
14. Stratification of Prognosis of Triple-Negative Breast Cancer Patients Using Combinatorial Biomarkers.
Yue Y; Astvatsaturyan K; Cui X; Zhang X; Fraass B; Bose S
PLoS One; 2016; 11(3):e0149661. PubMed ID: 26930401
[TBL] [Abstract][Full Text] [Related]
15. An associated classification of triple negative breast cancer: the risk of relapse and the response to chemotherapy.
Zhang J; Wang Y; Yin Q; Zhang W; Zhang T; Niu Y
Int J Clin Exp Pathol; 2013; 6(7):1380-91. PubMed ID: 23826420
[TBL] [Abstract][Full Text] [Related]
16. Residual cancer burden index and tumor-infiltrating lymphocyte subtypes in triple-negative breast cancer after neoadjuvant chemotherapy.
Pinard C; Debled M; Ben Rejeb H; Velasco V; Tunon de Lara C; Hoppe S; Richard E; Brouste V; Bonnefoi H; MacGrogan G
Breast Cancer Res Treat; 2020 Jan; 179(1):11-23. PubMed ID: 31529299
[TBL] [Abstract][Full Text] [Related]
17. Expression and Clinical Significance of Claudin-7, PDL-1, PTEN, c-Kit, c-Met, c-Myc, ALK, CK5/6, CK17, p53, EGFR, Ki67, p63 in Triple-negative Breast Cancer-A Single Centre Prospective Observational Study.
Constantinou C; Papadopoulos S; Karyda E; Alexopoulos A; Agnanti N; Batistatou A; Harisis H
In Vivo; 2018; 32(2):303-311. PubMed ID: 29475913
[TBL] [Abstract][Full Text] [Related]
18. Prognostic markers in triple-negative breast cancer.
Rakha EA; El-Sayed ME; Green AR; Lee AH; Robertson JF; Ellis IO
Cancer; 2007 Jan; 109(1):25-32. PubMed ID: 17146782
[TBL] [Abstract][Full Text] [Related]
19. Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy.
Luen SJ; Salgado R; Dieci MV; Vingiani A; Curigliano G; Gould RE; Castaneda C; D'Alfonso T; Sanchez J; Cheng E; Andreopoulou E; Castillo M; Adams S; Demaria S; Symmans WF; Michiels S; Loi S
Ann Oncol; 2019 Feb; 30(2):236-242. PubMed ID: 30590484
[TBL] [Abstract][Full Text] [Related]
20. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients.
Yau C; Osdoit M; van der Noordaa M; Shad S; Wei J; de Croze D; Hamy AS; Laé M; Reyal F; Sonke GS; Steenbruggen TG; van Seijen M; Wesseling J; Martín M; Del Monte-Millán M; López-Tarruella S; ; Boughey JC; Goetz MP; Hoskin T; Gould R; Valero V; Edge SB; Abraham JE; Bartlett JMS; Caldas C; Dunn J; Earl H; Hayward L; Hiller L; Provenzano E; Sammut SJ; Thomas JS; Cameron D; Graham A; Hall P; Mackintosh L; Fan F; Godwin AK; Schwensen K; Sharma P; DeMichele AM; Cole K; Pusztai L; Kim MO; van 't Veer LJ; Esserman LJ; Symmans WF
Lancet Oncol; 2022 Jan; 23(1):149-160. PubMed ID: 34902335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
